Pro Medicus Limited provides radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualization solutions worldwide. It offers medical software for practice management; integration products; Promedicus.net secure email; healthcare software that provides radiologist and clinicians with advanced visualization capability for viewing 2-D, 3-D, and 4-D medical images; and PACS/Digital imaging software. The company offers its products under the Visage RIS, Visage RIS/PACS, and Visage 7 names. It also provides Visage Ease Pro, a mobile applications, which allow users access to medical imaging results that are stored on a Visage 7 server; training, installation, and professional services; and after sale support and service products. The company offers its products and services to hospitals, diagnostic imaging groups, and other health related entities. Pro Medicus Limited was founded in 1983 and is headquartered in Richmond, Australia.
Industry, Sector and Symbol
Industry Health Information Services
Sub-IndustryN/A
SectorComputer and Technology
CIKN/A
Phone61 3 9429 8800
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$45.39 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable
Pro Medicus (ASX:PME) Frequently Asked Questions
What is Pro Medicus' stock symbol?
Pro Medicus trades on the ASX under the ticker symbol "PME."
How often does Pro Medicus pay dividends? What is the dividend yield for Pro Medicus?
Pro Medicus announced a Final dividend on Monday, February 25th. Stockholders of record on Friday, May 17th will be paid a dividend of 0.025 per share on Friday, May 17th. This represents a dividend yield of 0.18%. The ex-dividend date of this dividend is Tuesday, March 12th. View Pro Medicus' Dividend History.
Has Pro Medicus been receiving favorable news coverage?
News stories about PME stock have been trending very positive this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Pro Medicus earned a media sentiment score of 3.2 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Pro Medicus.
Who are some of Pro Medicus' key competitors?
Some companies that are related to Pro Medicus include Compugroup Medical (COP), Craneware (CRW), Sensyne Health (SENS), Alcidion Group (ALC), Mach7 Technologies (M7T), Kneat.com (KSI), Medadvisor (MDR), Reliq Health Technologies (RHT), Vitalhub (VHI), CogState (CGS), 1ST Group (1ST), Oneview Healthcare (ONE), Diagnos (ADK), ICSGlobal (ICS) and Jayex Healthcare (JHL).
What other stocks do shareholders of Pro Medicus own?
Who are Pro Medicus' key executives?
Pro Medicus' management team includes the folowing people:
- Dr. Sam Aaron Hupert, Co-Founder, Deputy Chairman, CEO & MD
- Mr. Anthony Barry Hall, Co-Founder, Technology Director & Exec. Director
- Dr. Malte Westerhoff, Global Chief Technology Officer
- Mr. Brad Levin, GM of North America & Global Head of Marketing
- Mr. Danny Tauber, Gen. Mang. of Australia
What is Pro Medicus' stock price today?
One share of PME stock can currently be purchased for approximately A$28.57.
How big of a company is Pro Medicus?
What is Pro Medicus' official website?
How can I contact Pro Medicus?
The company can be reached via phone at 61 3 9429 8800.
MarketBeat Community Rating for Pro Medicus (ASX PME)
MarketBeat's community ratings are surveys of what our community members think about Pro Medicus and other stocks. Vote "Outperform" if you believe PME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PME will underperform the S&P 500 over the long term. You may vote once every thirty days.
